@article{oai:nagasaki-u.repo.nii.ac.jp:00015742,
 author = {柴田, 尚武 and 森, 和夫 and 森山, 忠良 and 田中, 敬生 and 萬木, 二郎},
 issue = {10},
 journal = {Neurologia medico-chirurgica},
 month = {Oct},
 note = {During periods from January, 1981 to December, 1983, 51 patients (31 malignant astrocytomas, 17 glioblastomas, and others 3) were treated with radiochemotherapy using Nimustine hydro-chloride, ACNU (group B) and radiochemoimmunotherapy with Picibanil^<(R)>, OK-432 (group A) by randomized controlled study. Group A consisted of 24 patients and group B of 27 patients. The differences in the background of the two groups were not statistically significant. Survival curves of both groups were shown by the Kaplan-Meier method. The postoperative survival rate at 1 year and 2 years were 70% and 30%, respectively, equal in both groups, and the differences between groups A and B were not statistically significant by the Cox-Mantel test. The side effects by group B therapy were most prominent in the bone marrow, and severe leukopenia occurred. However, group A therapy suppressed leukopenia after 2 months. Immunological parameters, such as purified protein derivative skin reaction test did not change, but streptococcal Su-polysaccharide skin reaction test became positive after group A therapy., Neurologia medico-chirurgica, 25(10), pp.832-836; 1985},
 pages = {832--836},
 title = {悪性グリオーマに対する術後放射線化学免疫療法 : 51例3年間の randomized controlled study},
 volume = {25},
 year = {1985}
}